
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca Inc. demonstrates a strong positive outlook due to its promising clinical pipeline, which includes innovative treatments that target the RAS/MAPK pathway, specifically Naporafenib for NRASm melanoma and various other solid tumors. The company reports encouraging median overall survival (mOS) results of 13.0 to 14.1 months, significantly surpassing traditional therapies, which positions its combination therapies favorably in the market. Furthermore, the anticipated upcoming catalysts, including pivotal trial data filings for its lead compounds ERAS-0015 and ERAS-4001 expected in 2025 and 2026 respectively, add to its growth potential despite shares currently trading at cash value.
Bears say
Erasca Inc. has demonstrated limited efficacy in its clinical trials, particularly evident in the SEACRAFT-1 study, which reported a mere 23% response rate among non-melanoma tumor types, indicating challenges in addressing the complex feedback mechanisms in MAPK-mutated tissues. The company experienced a significant increase in net loss, reporting $63.2 million, or ($0.29 per share), for the second quarter of 2024, compared to a net loss of $31.7 million, or ($0.21 per share), in the same period the previous year. These financial struggles, coupled with the clinical effectiveness issues faced in their development pipeline, contribute to a negative outlook for Erasca's stock.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares